Treatment

Combination therapy has transformed treatment for advanced thyroid cancers, especially aggressive anaplastic thyroid cancer (ATC) and radioiodine-refractory differentiated thyroid cancer (DTC). By targeting multiple pathways at once, these approaches overcome resistance and significantly improve patient outcomes compared with traditional single therapies. A major advance is the FDA-approved combination of dabrafenib and trametinib for BRAF V600E–mutated […]

Zusduri is the first FDA-approved targeted, non-surgical treatment for recurrent low-grade, intermediate-risk non–muscle invasive bladder cancer. It delivers mitomycin C directly into the bladder using RTGel® technology, which turns from liquid to gel at body temperature. This allows the drug to stay in contact with the bladder wall for hours, maximizing local effect while minimizing